{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T16:39:34Z","timestamp":1760978374495},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1093\/annonc\/mdf273","type":"journal-article","created":{"date-parts":[[2002,11,6]],"date-time":"2002-11-06T21:18:26Z","timestamp":1036617506000},"page":"1568-1575","source":"Crossref","is-referenced-by-count":74,"title":["A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"N.C.","family":"Tebbutt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Iveson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hickish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Maisey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mochlinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf273_bb0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf273_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0305-7372(88)90025-4","article-title":"Chemotherapy of gastric cancer","volume":"15","author":"Preusser","year":"1988","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdf273_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0305-7372(98)90077-9","article-title":"Medical management of advanced gastric cancer","volume":"24","author":"Hill","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdf273_bb0025","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2000.18.14.2648","volume":"18","author":"Vanhoefer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2168.2001.01655.x","article-title":"One-year survey of carcinoma of the oesophagus and stomach in Wales","volume":"88","author":"Pye","year":"2001","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdf273_bb0040","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V","article-title":"Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions","volume":"82","author":"Repetto","year":"1998","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf273_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00000421-198808000-00010","article-title":"Continuous 5-fluorouracil infusion in advanced gastric carcinoma","volume":"11","author":"Moynihan","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/oxfordjournals.annonc.a057914","article-title":"High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer","volume":"2","author":"Louvet","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0060","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/oxfordjournals.annonc.a059017","article-title":"Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer","volume":"5","author":"Vanhoefer","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0277-5379(89)90273-3","article-title":"Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro","volume":"25","author":"Russello","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf273_bb0075","series-title":"Grading of Toxicity. Manual of Oncologic Therapeutics","first-page":"519","author":"Macdonald","year":"1995"},{"key":"10.1093\/annonc\/mdf273_bb0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00435732","article-title":"Testing the EORTC Quality of life questionnaire on cancer patients with heterogeneous diagnoses","volume":"2","author":"Ringdal","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdf273_bb0085","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO.1995.13.5.1249","article-title":"Test\/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire","volume":"13","author":"Hjermstad","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0090","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008263516099","article-title":"A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer","volume":"8","author":"Ross","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0095","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2002.09.029","article-title":"Multi-centre randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin-C (MMC) in inoperable pancreatic cancer","volume":"20","author":"Maisey","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdf273_bb0105","first-page":"185","article-title":"Asymptotically efficient invariant procedures","volume":"135","author":"Peto","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1093\/annonc\/mdf273_bb0110","series-title":"Analysis of Survival Data","author":"Cox","year":"1984"},{"key":"10.1093\/annonc\/mdf273_bb0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/bjc.1993.75","article-title":"High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma","volume":"67","author":"Highley","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf273_bb0120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1991.9.5.827","article-title":"Sequential high-dose methotrexate and fluorouracil combined with doxorubicin\u2014a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group","volume":"9","author":"Wils","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf273_bb0125","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"A prospective randomised trial comparing MCF with ECF in advanced oesophago-gastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/10\/1568\/399970\/mdf273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:33:47Z","timestamp":1582166027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419637671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0923753419637671"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf273","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}